Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin.

Etymologies

Sorry, no etymologies found.

Examples

  • Novartis said the Swiss company and partner Human Genome Sciences Inc. will stop development of chronic hepatitis C compound albinterferon alfa-2b.

    Novartis Cites Discontinued Drugs for Charge

  • The decision comes after Novartis said in October it will stop the development of chronic hepatitis C compound albinterferon alfa-2b and also end research of Mycograb, an antifungal agent.

    Novartis Ends Work on Drug

  • Novartis has withdrawn its MAA for Joulferon® (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

    GEN News Highlights

  • In both studies half the injections of albinterferon alfa-2b achieved sustained virologic response comparable to that achieved by peginterferon alfa-2a, they add.

    GEN News Highlights

  • Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN ™) for the treatment of chronic hepatitis C.

    THE MEDICAL NEWS

  • Novartis will be responsible for commercialization of albinterferon alfa-2b in the rest of the world under the brand name Joulferon, and will pay HGS a royalty on those sales.

    SeekingAlpha.com: Home Page

  • Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that Novartis has withdrawn a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market JOULFERON® (albinterferon alfa-2b, known in the United States as ZALBIN ™) for the treatment of chronic hepatitis C.

    THE MEDICAL NEWS

  • In both studies half the injections of albinterferon alfa-2b achieved sustained virologic response comparable to that achieved by peginterferon alfa-2a, they add.

    GEN News Highlights

  • Novartis has withdrawn its MAA for Joulferon® (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

    GEN News Highlights

  • Novartis has withdrawn its MAA for Joulferon® (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

    GEN News Highlights

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.